• Happy New Year
    Happy New Year

    Happy CACA 10 year Anniversary

  • Pittcon 2009
    Pittcon 2009

    Pittcon 2009, Chicago, March 2009

  • HPLC 2010
    HPLC 2010

    HPLC 2010, Boston, June 2010

  • Pittcon 2011
    Pittcon 2011

    Pittcon 2011, Atlanta, March 2011

  • Pittcon 2012
    Pittcon 2012

    Pittcon 2012, Orlando, March 2012

  • HPLC 2012
    HPLC 2012

    HPLC 2012, Anaheim, June 2012

  • Pittcon 2014
    Pittcon 2014

    Pittcon 2014, Chicago, March 2014

Date:                     Wednesday, Feb 28, 2024, 12:00 pm – 1:00 pm EST

Registration Link: https://register.gotowebinar.com/register/2770900580918426720

Event Overview:

Oligonucleotides are nucleic acids that can be used to modulate gene expression via a range of processes, including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation, and programmed gene editing. Many pharmaceutical companies are exploiting the usage of oligonucleotides as an emerging therapeutic modality. Numerous chromatographic methods have been developed for the analysis of these oligonucleotides. The hydrophilic nature and the easily formed adducts have posed a significant challenge to developing LC-MS/MS methods. We will present three case studies where we have optimized the bioanalytical methods for analyzing oligonucleotides.

Key Learning Objectives:

·         Review the fundamental mechanisms of oligonucleotide therapeutics.

·         Learn the promising approaches in optimizing the LC-MS/MS method for determining oligonucleotide and metabolite through three cases.

Who Should Attend:

  • Scientists who develop and/or manage LC-MS/MS methods for oligonucleotides.
  • Lab managers leading teams involved with the analysis of oligonucleotides.

Speaker’s bio:

Xiangji Liu graduated from the University of Georgia with a chemistry and molecular biology background. He joined Frontage Laboratories, Inc. in 2021 and has served nearly one hundred bioanalytical projects from pharmaceutical companies worldwide. He mainly manages a compliance bioanalytical group. He leads the team in the bioanalysis of small molecules, oligonucleotides, and proteins using LC-MS and the bioanalysis of bound and unbound metals using ICP-MS. He supports the pharmacokinetics analysis of small interfering RNA (siRNA) therapeutics in the preclinical and phase I clinical stages. He is also a guest associate editor of the journal “Frontiers in Pharmacology-Pharmacology of Infectious Diseases.”